

DOCUMENT 29

ARR226-1924



Results to Date from the PFOA Worker Study

Ammonium Perfluorooctanoate: Cross-Sectional Surveillance of Clinical Measures of General Health Status Related to a Serum Biomarker of Exposure and Retrospective Cohort Analyses in a Polymer Production Plant

Robin C. Leonard, Ph.D.

Principal Epidemiologist, DuPont Haskell Laboratory for
Health and Environmental Sciences

EPA, January 10, 2005

1



Agenda

- Purpose of Study
- General methodology
- Results to date (clinical pathology parameters)
- Summary
- Timeline
- Further Work



Purpose of Study

- Primary objectives :
 - Develop statistical models that *describe the relationship of serum PFOA to health outcome variables* suggested by previous animal and worker studies, taking into account potential confounders and effect modifiers.
 - Conduct retrospective cohort mortality analyses using appropriate stratification based on estimated past exposures to PFOA.

29



General Methodology

- Voluntary participation across all areas of the plant
- Cross-sectional design, that is, “snapshot” of both the exposure marker and the health outcome variables
 - Cross-sectional studies address “person and place”, but not “time”—the descriptive triad of epidemiology
 - No data collected over time, no baseline
 - Cannot determine causality, only identify associations
- Logistic, linear, and quadratic regression analyses for modeling
- Deciles of exposure used for internal comparisons



Results from Clinical Chemistries

- 1,024 employees participated in the cross-sectional health surveillance
 - All participants have received their individual serum PFOA levels and medical test results
 - 62 parameters have been analyzed
- Not all of the questionnaire data have been analyzed, but these analyses are underway
- Retrospective cohort analyses not completed
 - NDI data received Dec. 21, 2004



General Findings

- Most of the parameters measured were within normal reference ranges and not associated with serum PFOA levels.
- There were statistically significant ($p \leq 0.05$) modest increases in some cholesterol fractions (total, LDL) and triglycerides with higher concentrations of serum PFOA.
- HDL cholesterol was not associated with serum PFOA levels.
 - As expected, age, body mass index, and alcohol consumption were also contributors to increases in lipids.
- CRP levels (C-reactive protein) were not associated with serum PFOA levels.



General Findings

- There were no consistent relationships between results of liver tests and serum PFOA concentrations.
 - Different responses in males and females
 - Alcohol consumption was a factor, but inconsistent as to category and between genders
- There were statistically significant, but slight, increases in uric acid and iron with higher concentrations of serum PFOA.
 - Increased uric acid has been associated with increased lipids.



Serum PFOA Levels By Work Assignment

Work Assignment	Serum PFOA (ppb)			
	Number in Group	Median	Min	Max
Works in PFOA areas	259	490	17	9550
Previously worked in PFOA areas	264	200	9	2590
Occasionally works in PFOA areas	160	180	8	2070
Never assigned to PFOA areas	342	110	5	963
Total Participants	1025			





Context for Cholesterol Levels

- Male study participants' total cholesterol and LDL levels were compared to U.S. males using NHANES data.

- Study participants had a smaller percentage of males with high cholesterol than the U.S. population, except for the top decile of serum PFOA.

Overall Comparison of Male Washington Works Study Participants with the General US Population









Lipid Fractions Unadjusted: Males


Excludes those on
lipid-lowering meds

Simple charts of mean
unadjusted lipid values
for exposure decile
indicate a small
increase in last decile.




DUPONT

Lipid Fractions Adjusted for Age, BMI, Alcohol: Males



Mean adjusted lipid values for serum PFOA levels indicate a modest increase in highest decile (>1000 ppb)




CHOL_TOTAL by PFOA Quantile

DUPONT

Sex=M, Heartmeds=N, WH 2004

	198.823	187.018	205.629	198.857	196.306	204.635	200.871	198.873	206.097	214.587
Mean	198.823	187.018	205.629	198.857	196.306	204.635	200.871	198.873	206.097	214.587
Std Dev	32.345	28.787	39.434	31.099	37.476	32.835	30.472	31.022	38.740	38.648
Nobs	625.000									



DU PONT

CHOL_TOTAL by PFOA Quantile

Sex=F, Heartmeds=N, MU 2004


Mean	180.887	Std Dev	38.111	n	171.045	201727	197.318	185.50	208.478	205.638	208.045	208.000	213.091
Mean	180.887	Std Dev	38.111	n	171.045	201727	197.318	185.50	208.478	205.638	208.045	208.000	213.091

Mean
Nobs

□

□

CHOL_TOTAL



□ 0240



LOG_Chol_Total: MALES, WW 2004 Results of Regression Modeling

Where Sex=M, Heartmeds=No

Source	DF	SS	MS	FValue	ProbF
Model	4	0.78955	0.19739	6.88	<.0001
Error	620	17.78688	0.02869	—	—
Corrected Total	624	18.57643	—	—	—

Parameter Estimates

Variable	DF	Estimate	stdErr	tValue	ProbT	Sex=M
Intercept	1	4.99553	0.06366	78.47	<.0001	Med=No
LOG_PFOA	1	0.02307	0.00623	3.70	0.0002	
BMI	1	0.00357	0.00158	2.27	0.0238	
AGE	1	0.00153	0.00077841	1.97	0.0491	
ALC6	1	-0.07070	0.03469	-2.04	0.0420	
R-Square		0.042503				

Where Sex=M, Heartmeds=B (B=all subjects)

Source	DF	SS	MS	FValue	ProbF
Model	2	0.43865	0.21932	7.11	0.0009
Error	778	23.98564	0.03083	—	—
Corrected Total	780	24.42429	—	—	—

Parameter Estimates

Variable	DF	Estimate	stdErr	tValue	ProbT	Sex=M
Intercept	1	5.17480	0.03196	161.93	<.0001	Med=B
LOG_PFOA	1	0.01921	0.00574	3.34	0.0009	
ALC6	1	-0.05789	0.03170	-1.83	0.0683	
R-Square		0.017960	EPA, January 10, 2005			



LOG_Chol_Total : FEMALES, WW 2004

Results of Regression Modeling

Source	DF	SS	MS	FValue	ProbF
Model	4	1.00313	0.25078	7.73	<.0001
Error	213	6.91462	0.03246	—	—
Corrected Total	217	7.91775	—	—	—


Parameter Estimates: Sex=F, Heartmeds=NO						
Source	Variable	DF	Estimate	StdErr	tValue	Prob
Model	Intercept	1	4.84428	0.08752	55.35	<.0001
	LOG_PFOA	1	0.02381	0.01161	2.05	0.0415
	BMI	1	0.00413	0.00195	2.11	0.0358
	AGE	1	0.00474	0.00141	3.36	0.0009
	ALC2	1	0.39119	0.18144	2.16	0.0322
R-Square			0.126694			

Source	DF	SS	MS	FValue	ProbF
Model	4	1.04587	0.26147	8.36	<.0001
Error	238	7.43958	0.03126	—	—
Corrected Total	242	8.48546	—	—	—

Parameter	Estimates: Sex=F, Heartmeds=B	Variable	DF	Estimate	StdErr	tValue	Prob
Intercept	4.86657	0.07935	61.33	<.0001			
LOG_PFOA	0.02283	0.01067	2.14	0.0334			
BMI	0.00475	0.00178	2.68	0.0080			
AGE	0.00383	0.00127	3.01	0.0029			
ALC2	0.40589	EPA, January 17, 2005	2.28	0.0234			
R-Square	0.123255						


LOG_Chol_Total vs LOG_PFOA : WW 2004, Terms=LogPFOA BMI AGE ALC6

Where Sex=M, Heartmeds=NO




LOG_Chol_Total vs LOG_PFOA : WW 2004, Terms= LogPFOA ALC6

Where Sex=M, Heartmeds=B




LOG_Chol_Total vs LOG_PFOA : WW 2004, Terms= LogPFOA BMI AGE ALC2

Where Sex=F, Hear tmeds=No,



LOG_Chol_Total vs LOG_PFOA : WW 2004, Terms= LogPFOA BMI AGE ALC2

Where Sex=F, Heartmeds=B




DUPONT

URIC_ACID by PFOA Quantile

Sex=M, Heartmeds=B, WW 2004

	Mean	1735	1755	1822	1828	1820	1805	1810	1816	1.777	1.875
	Std Dev	0.188	0.209	0.179	0.183	0.177	0.189	0.205	0.205	0.180	0.178

Mean
Nobs
1805
781000




DUPONT

URIC_ACID by PFOA Quantile
Sex=F, Heartmeds=B, MM 2004

	1410	1.34	1485	1483	1542	1533	1568	1552	1.594	1.582
Mean	1.410	1.34	1.485	1.483	1.542	1.533	1.568	1.552	1.594	1.582
Std Dev	0.213	0.309	0.285	0.287	0.195	0.192	0.275	0.242	0.175	0.222


Mean 1.508
Nobs 243.000



49

LOG_URIC_ACID vs LOG_PH_OA: WW 2004, !erms=LogPH_OA BM! ALCA


Where Sex=M, Heartmarks=R



DU PONT


LOG₁₀_URIC_ACID vs LOG₁₀_PFOA: WW 2004, Terms= LogPFOA BMI AGE

Where Sex=F, Hear tmeds=B




LOG_{_}URIC_ACID vs LOG_{_}PFOA: CLEANED, Terms= LogPFOA BMI AGE

Where Sex=F, Heartmeds=B



LOG_E_URIC_ACID vs LOG_PFOA: CLEANED, Terms= LogPFOA BMI ALC4

Where Sex=M, Heartmeds=B




IRON by PFOA Quantile

Sex=M, Heartmeds=B, MM 2004

Mean	4.545	4.670	4.568	4.672	4.668	4.621	4.66	4.699	4.622	4.737
Std Dev	0.364	0.304	0.349	0.307	0.336	0.331	0.34	0.345	0.327	0.355

Mean
Nobs


4.642
78100



IRON by PFOA Quantile

Sex=F, Heartmeds=B, MN 2004

	4.566	4.362	4.269	4.474	4.471	4.393	4.454	4.457	4.520	4.592
Mean	4.566	4.362	4.269	4.474	4.471	4.393	4.454	4.457	4.520	4.592
Std Dev	0.359	0.445	0.583	0.401	0.345	0.395	0.369	0.334	0.278	0.354



IRON by PFOA Quantile

Sex=B, Heartmeds=B, MM 2004


Mean	4.513	4.524	4.577	4.572	4.582	4.631	4.587	4.647	4.641	4.707
Std Dev	0.380	0.434	0.373	0.342	0.351	0.385	0.333	0.303	0.317	0.367

Mean
Nobs

4.598


1024.000

LOG_Iron




LOG_Iron vs LOG_PFOA: CLEANED, Terms= LogPFOA BMI

Where Sex=M, Heartmeds=B



LOG_Iron vs LOG_PFOA: CLEANED, Terms= LogPFOA BMI

Where Sex=F, Heartmeds=B





Summary

- *To date, there are no human health effects known to be caused by PFOA; several statistical observations merit further study.*
 - Statistically significant associations are seen with serum PFOA levels and some serum lipid fractions, uric acid, and iron.
 - These associations were only seen in those study participants with the highest serum PFOA levels, which were equal to or greater than 1000 ppb.
 - DuPont, in collaboration with outside experts, is committed to conducting the studies that are necessary to understand the significance of these observations.

EPA, January 10, 2005



Timeline 2004

Epidemiology Study Timeline

	A P r	M a y	J u n	J u n	A u g	S e p	O c t	N o v	D e c	1Q e p	2Q t v	05	05
Design, identification of contractors, approvals from review boards													
Operations and logistics planning, employee communications													
Clinical examinations, blood draw													
Electronic data capture/transfer/QA													
Initiate statistical analyses, draft methods, outline results section, meet with ERB													
Draft Final Report (Cross-sectional analyses)													
Draft Final Report (Cohort Mortality analyses)													

EPA January 10, 2005



Plans for Further Work

DuPont Medical, Epidemiology, and Toxicology will work with medical and scientific advisors to design studies to answer remaining questions:

Are these observations reproducible?

Are similar associations seen in other worker populations?

Is there a cause and effect?

Is there a biological basis of these associations?